GLP-1 receptor agonists, which can cost around $1,300 a month, have caused an increase in premiums that “affect all members, ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 502.93% and ...

The biotech sector witnessed a see-saw performance in 2024. While the year started on a positive note, much of the gains ...

The US FDA approved Eli Lilly's Zepbound as the first ever medication for obstructive sleep apnea for patients who also have ...

Novo Nordisk NVO has achieved the primary endpoint in a late-stage study evaluating its next-gen subcutaneous obesity ...

The FDA has expanded the approval of Eli Lilly’s obesity medication Zepbound to include treating moderate to severe ...

Rhythm Pharmaceuticals said Friday that its weight-loss treatment gained expanded approval from the U.S. Food and Drug Administration to include children as young as two years old.

Eli Lilly is now comfortably ahead of Novo Nordisk in the race to dominate the market for obesity treatments.

The updates from clinical trials of Eli Lilly's competitors in the obesity market were largely underwhelming this year. See ...

America is suddenly getting healthier. No one knows why.

Powerful weight-loss drugs are expanding use of U.S. health care as patients starting prescriptions are diagnosed with ...